AXSM - Axsome Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Axsome Therapeutics, Inc.

200 Broadway
3rd Floor
New York, NY 10038
United States
212-332-3241
http://www.axsome.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees37

Key Executives

NameTitlePayExercisedYear Born
Dr. Herriot Tabuteau M.D.Founder, Chairman, CEO & Pres696kN/A1968
Mr. Nick PizzieCFO & Principal Accounting Officer374.12kN/A1975
Mr. Mark JacobsonSr. VP of Operations & Sec.N/AN/A1983
Dr. Cedric O'Gorman M.B.A., M.D., MBASr. VP of Clinical Devel. & Medical AffairsN/AN/A1975
Joseph Debrah-AffulDirector of Fin.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Corporate Governance

Axsome Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.